{
  "abstract": "Objectives Despite significant therapeutic progress in systemic lupus erythematosus (SLE), adopting a treat-to-target strategy remains challenging. While disease activity monitoring is well established, no standardized tool identifies patients needing treatment reassessment. The recently developed Lupus Check 5 (LC5) combines clinical, laboratory, and patient-reported data to address this gap. Our aim was to characterize an SLE cohort using the LC5 tool and identify factors associated with a flagged need for treatment review.Methods A cross-sectional study was conducted in SLE patients evaluated with the LC5 tool during routine or scheduled visits. Data were obtained from structured interviews and clinical records. LC5 includes five domains: (1) disease activity (SLEDAI-2K >=1), (2) persistent laboratory abnormalities (hematologic, renal, or serologic), (3) corticosteroid use > 5 mg/day, (4) urgent care or hospitalization for lupus flare, and (5) treatment-related concerns. Patients were flagged if at least one domain was positive. Categorical variables were analyzed using Chi-square or Fisher’s Exact tests, and continuous variables with the Mann-Whitney U test; variables with p < 0.2 entered univariate logistic regression.Results Of 81 eligible patients, 32 were included (74% female; median age 40 years [IQR 35–54]; median disease duration 10 years [IQR 5.3–13]). Mucocutaneous (84%), articular (81%), and hematologic (66%) manifestations predominated. Anti-dsDNA antibodies were positive in 75% and low complement in 47% at baseline. Hydroxychloroquine was used by 90%, and corticosteroids by 50%, with 19% taking > 5 mg/day. Median SLEDAI-2K was 0 (IQR 0–2), indicating low disease activity.Overall, 23 patients (71.9%) were LC5-positive. The most frequent domains were laboratory abnormalities (76%), disease activity (48%), treatment-related concerns (48%), corticosteroid use > 5 mg/day (36%), and recent hospitalization (20%). LC5 positivity correlated with anti-dsDNA positivity (OR 8.33; p = 0.02), corticosteroid use (OR 15.9; p = 0.018), and polypharmacy (>= 5 drugs; OR 7.20; p = 0.023). Trends were observed for younger age at diagnosis and longer disease durationAbstract PO:10:259 Figure 1Conclusions Despite low disease activity, most patients (71.9%) were flagged by LC5, mainly due to persistent laboratory abnormalities and ongoing corticosteroid use. LC5 may provide a practical, structured method to identify SLE patients requiring therapeutic optimization, meriting validation in prospective studies.",
  "authors": [
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Mariana Patela"
    },
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Catarina Silva"
    },
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Tiago Beirão"
    },
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Catarina Rua"
    },
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Tiago Meirinhos"
    },
    {
      "affiliations": [
        "Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal"
      ],
      "name": "Ana Sofia Pinto"
    }
  ],
  "title": "PO:10:259 The need for treatment review in SLE: application of the lupus check 5 (LC5)tool in a real-world cohort",
  "uid": "6168d26c-8b23-52f4-88b6-866d7243f1c2"
}